Vanguard Group’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-89,777
Closed -$45K – 4133
2017
Q2
$45K Hold
89,777
– – ﹤0.01% 4033
2017
Q1
$39K Hold
89,777
– – ﹤0.01% 4038
2016
Q4
$49K Hold
89,777
– – ﹤0.01% 4038
2016
Q3
$45K Hold
89,777
– – ﹤0.01% 4040
2016
Q2
$18K Buy
+89,777
New +$46.8K ﹤0.01% 4120

Vanguard Group's AST.WS Position: Q3 2017 in Review

Vanguard Group sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 89,777 shares — an estimated $45K sold.

Vanguard Group first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $49K in Q4 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Vanguard Group reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
  • Vanguard Group sold 89,777 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $45K.
  • Vanguard Group first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
  • Vanguard Group's Asterias Biotherapeutics Warrants position peaked at $49K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.

Based on Vanguard Group's 13F filing for Q3 2017, filed 14 Nov 2017.